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Summary
Telomere elongation by telomerase is repressed in cis by the telomeric protein TRF1. Tankyrase 1 poly(ADP-ribosyl)ates
TRF1 and releases it from telomeres, allowing access of telomerase to telomeres. Here we demonstrate that tankyrase 1
inhibition in human cancer cells enhances telomere shortening by a telomerase inhibitor and hastens cell death. Conversely,
either tankyrase 1 upregulation or telomere shortening, each of which decreased TRF1 loading on a chromosome end,
attenuated the impact of telomerase inhibition. These results are consistent with the idea that telomeres having fewer
TRF1s increase the efficiency of their elongation by telomerase. This study implies that both enzyme activity and accessibility
to telomeres can be targets for telomerase inhibition.
Introduction gene into human somatic cells produces telomerase activity
and extends their replicative capacity (Bodnar et al., 1998). In
mice, genetic disruption of TR abolishes telomerase activity andTelomeres are specialized nucleoprotein complexes that protect
the ends of eukaryotic chromosomes (reviewed in Blackburn, shortens telomeres (Blasco et al., 1997), resulting in reduced
oncogenesis in later generations (Greenberg et al., 1999). In the2001). Since DNA polymerases cannot replicate the ends of
linear DNA (end replication problem), telomeric DNA would grad- early stages of human carcinogenesis, increased cell division
accelerates telomere shortening. Consequently, human cancerually shorten after each cell cycle unless this problem was solved
by a telomere-synthesizing enzyme, telomerase. In most human cells often maintain shorter telomeres than do cells in sur-
rounding normal tissues (reviewed in Maser and DePinho, 2002).somatic tissues, telomerase activity is not detectable or is so
weak (Kim et al., 1994; Shay and Bacchetti, 1997; Masutomi et Thus, cancer cells bypass telomere crisis by activating te-
lomerase.al., 2003) that it cannot overcome telomere attrition. Critically
shortened telomeres directly elicit a DNA damage checkpoint Telomerase could be not only a powerful marker for cancer
diagnosis, but also a rational target for anticancer therapeuticsresponse (d’Adda di Fagagna et al., 2003), which results in
replicative senescence. Functionally intact telomeres can form (reviewed in Shay and Wright, 2002). In fact, overexpression
of dominant negative mutants of TERT represses telomerasea potentially protective structure, called a t loop, in which the
single-stranded telomeric terminus (3-overhang) folds back and activity, progressively shortens telomeres, and eventually kills
cancer cells (Hahn et al., 1999; Zhang et al., 1999). Continuousinvades the double-stranded region (Griffith et al., 1999). Loss
of the 3-overhang leads to prompt decapping of telomeres exposure to chemical telomerase inhibitors also shortens telo-
meres, followed by senescence or apoptosis (Naasani et al.,even if they are not critically short (van Steensel et al., 1998).
Thus, both length of the telomeric tract and status of its distal 1999; Damm et al., 2001; Seimiya et al., 2002; Asai et al., 2003).
One concern in this strategy is that there will be a lag phaseend would contribute to telomere capping.
In contrast to human somatic cells, telomerase is highly between the time telomerase is inhibited and when telomeres
shorten sufficiently to disrupt their capping function. Further-activated in germ and most cancer cells (Kim et al., 1994; Shay
and Bacchetti, 1997). Telomerase is composed of a ubiquitously more, the potentially long treatment time could allow for drug
resistance to occur, which is a severe challenge to chemother-expressed RNA template, TR (or TERC), and a catalytic subunit,
TERT, whose expression correlates with telomerase activity (re- apy. Although there is no evidence that telomerase inhibition is
toxic prior to the point at which short telomeres start triggeringviewed in Nugent and Lundblad, 1998). Introduction of the TERT
S I G N I F I C A N C E
Telomere maintenance by telomerase allows human cancer cells to divide indefinitely. Telomerase inhibitors are expected to
selectively kill cancer cells by resuming the “end replication problem” of linear chromosomal DNA. However, therapeutic outcome
as a result of this strategy must await the emergence of a critically shortened telomere, which would require a long treatment
duration. Since cancer has a robust ability to evolve, continuous exposure to the same anticancer stress carries the risk of acquired
drug resistance,a seriousproblem incancer chemotherapy.Wedemonstrate that pharmacological targetingof tankyrase 1enhances
telomere shortening by means of a telomerase inhibitor and results in earlier cellular crisis. This study provides insight into strategies
for telomere-based molecular cancer therapeutics.
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DNA damage responses, intracellular uptake of a telomerase see the effect of exogenous tankyrase 1 (FN-tankyrase1; tagged
with a FLAG epitope and an NLS at the N terminus) exclusivelyinhibitor is sometimes reduced during prolonged treatment of
cancer cells (Naasani et al., 1999). Also, in general, increased in the nucleus. HTC75 fibrosarcoma cells were infected with
FN-tankyrase 1 retrovirus, and the transduced populations werehepatic metabolism often explains reduced action of drugs.
Accordingly, the potential ability to accelerate the rate of telo- further infected with a dominant negative mutant of human TERT
(DN-hTERT) (Hahn et al., 1999). Consistent with previous reportsmere shortening has profound implications for earlier induction
of crisis and thereby reduced risk of drug resistance. So far, (Hahn et al., 1999; Zhang et al., 1999), overexpression of DN-
hTERT repressed telomerase activity (Figure 1A) and decreasedfactors that modulate the effects of telomerase inhibitors have
not been described. the telomere length (Figure 1B). On the other hand, overexpres-
sion of FN-tankyrase 1 downregulated TRF1 and progressivelyIn telomerase-positive cells, telomere length is maintained
at a constant average value. This equilibrium is mediated by a increased telomere length (Smith and de Lange, 2000) without
affecting telomerase activity (Figures 1A and 1B). As expected,negative feedback regulation of telomerase where a “protein-
counting” mechanism discriminates the number of telomeric telomere elongation by FN-tankyrase 1 was completely abol-
ished by DN-hTERT in spite of TRF1 loss. After 60 populationproteins bound to a telomere (reviewed in Smogorzewska and
de Lange, 2004). Thus, longer telomeres recruit a greater num- doublings (PD) of the FN-tankyrase 1/DN-hTERT-double in-
fectants, DN-hTERT expression was lost and telomerase wasber of telomeric proteins that inhibit telomere elongation in cis.
In humans, this mechanism involves TRF1, a duplex telomeric reactivated (data not shown); these phenomena are often ob-
served in DN-hTERT-transfected cancer cells (Zhang et al.,repeat binding protein. Overexpression of TRF1 in telomerase-
positive cells results in telomere shortening, whereas its domi- 1999). The resulting populations maintained a high level of
FN-tankyrase 1 expression (data not shown) and exhibited telo-nant negative mutant induces elongation (van Steensel and de
Lange, 1997). Poly(ADP-ribosyl)ation of TRF1 by a telomeric mere elongation (Figure 1B). These observations verify that telo-
mere elongation by tankyrase 1 depends on telomerase activitypoly(ADP-ribose) polymerase (PARP), tankyrase 1, leads to loss
of its DNA binding activity (Smith et al., 1998; Loayza and de and is therefore blocked by telomerase inhibition.
Overexpression of a dominant negative TRF1 (DN-TRF1),Lange, 2003) and subsequent degradation of TRF1 (Chang et
al., 2003). Although tankyrase 1 has no recognizable nuclear which inhibits the telomere binding of endogenous TRF1, also
induces telomere elongation without affecting telomerase activ-localization signal (NLS), it is present in the nucleus as well as
the cytoplasm (Smith and de Lange, 1999; Cook et al., 2002; ity in HT1080 cells (Figures 1C and 1D, van Steensel and de
Lange, 1997). DN-hTERT also inhibited telomere elongation bySeimiya and Smith, 2002). Nuclear localization of tankyrase 1
requires interaction with TRF1, which contains an NLS (Smith DN-TRF1 (Figures 1C and 1D). In agreement with an earlier
report that TRF1 inhibits telomeric association of hTERT (Sharmaand de Lange, 1999). Overexpression of NLS-tagged tankyrase
1 in telomerase-positive cells releases TRF1 from telomeres et al., 2003), these observations indicate that FN-tankyrase 1
and DN-TRF1 elongate telomeres by allowing access of telome-and induces their elongation (Smith and de Lange, 2000). This
suggests that tankyrase 1 may alleviate the effect of telomerase rase to telomeres.
inhibitors by accelerating access of residual telomerase activity
to telomeres. Since shortened telomeres increase the efficiency Tankyrase 1 confers resistance
to telomerase inhibitorsof telomere elongation (Marcand et al., 1999; Ouellette et al.,
2000; Hemann et al., 2001), telomere shortening per se may While dominant negative mutants (Hahn et al., 1999; Zhang et
al., 1999) or small interfering RNAs (Masutomi et al., 2003) foralso result in decreased sensitivity to telomerase inhibitors.
This study demonstrates that tankyrase 1 diminishes the hTERT are probably the most specific and powerful agents for
telomerase inhibition, there would be no effect on a small frac-effect of telomerase inhibitors in telomerase-positive cells. Fur-
thermore, during progressive shortening, telomeres became tion of the cells that lost or did not incorporate those exogenous
genes. This situation makes it difficult to explore the intrinsicmore resistant to a telomerase inhibitor. PARP inhibitors that
could inhibit tankyrase 1 eliminated these problems and en- mechanisms that modulate the impact of continuous telomerase
inhibition. Thus, we next used a synthetic telomerase inhibitor,hanced telomere shortening. This report demonstrates a spe-
cific enzyme that can modulate the impact of telomerase inhibi- MST-312 (Seimiya et al., 2002; Supplemental Table S1), that
had been developed by taking a hint from telomerase-inhibitorytion on cancer cells.
activity of ()-epigallocathechin gallate (EGCG) (Naasani et al.,
1998). Continuous treatment of HTC75 cells with nontoxic dosesResults
of MST-312 induced gradual shortening of telomeres (22.5
bp/PD, Figure 2A). Since shortened telomeres tended to beTelomere elongation by tankyrase 1 is blocked
by telomerase inhibition more resistant to further shortening (see below), we increased
the concentration from 1 M to 2 M during the course ofTelomere elongation by tankyrase 1 correlates with telomerase
activity (Cook et al., 2002; Chang et al., 2003). Thus, we first cultivation. Essentially, the cells in the presence of MST-312
grew at a comparable or slightly slower rate than that of un-examined whether telomere elongation by tankyrase 1 is
blocked by telomerase inhibition. Since the amount of intracellu- treated cells. However, atPD85, MST-312 reduced the growth
rate (Figure 2B). At the time, the cells exhibited a flattenedlar TRF1, which is required for nuclear localization of tankyrase
1, is usually too small to interact with excess amounts of exoge- morphology and expressed the senescence-associated -galac-
tosidase (SA--Gal), both of which are potential biomarkers fornous tankyrase 1, we introduced an NLS at the N terminus of
tankyrase 1 (Smith and de Lange, 2000). While tankyrases are cellular aging (Figure 2C). Finally, the cells externalized phos-
phatidylserine and exhibited a sub-G1 fraction, both of whichthought to have an innate role in cytoplasmic events (Chi and
Lodish, 2000; Lyons et al., 2001), this modification allows us to are characteristic of apoptosis (Figure 2D). Furthermore, the
26 CANCER CELL : JANUARY 2005
A R T I C L E
Figure 1. DN-hTERT inhibits telomere elongation by FN-tankyrase 1 and DN-TRF1
A: HTC75 cells were infected with pLPC (empty) or FN-tankyrase 1 retroviruses and then with pLNCX2 (empty) or HA-tagged DN-hTERT retroviruses. Upper
panels, Western blot analysis (20 g of proteins per lane) of whole cell (tankyrase, DN-hTERT, -tubulin) or nuclear extracts (TRF1, TRF2, lamin A/C) at PD8.
Molecular mass markers (kDa) are indicated at the right. Bottom, telomerase activity determined by in vitro TRAP assay. Each lysate was examined in
duplicate.
B: Change in telomere length of the cells in A. Genomic DNA was prepared at indicated population doublings (PD) and digested with HinfI and RsaI.
Telomeric restriction fragments (TRF) were detected by Southern blot analysis.
C: HT1080 cells were infected with a Myc-tagged DN-TRF1 retrovirus and then with pLNCX2 or HA-tagged DN-hTERT retroviruses. Upper panels, Western blot
analysis of whole cell or nuclear extracts at PD8. Bottom, telomerase activity in each cell lysate.
D: Change in telomere length of the cells in C.
p21 cyclin-dependent kinase inhibitor was induced, and the observations suggest that decrease in the number of telomere-
bound TRF1 allows access of residual telomerase activity toproapoptotic caspase-3 was activated (data not shown). These
changes were not observed at the earlier stage of passage. telomeres and therefore alleviates the effects of telomerase in-
hibitors.MST-312 had no effect on telomere length (determined by
Southern blot [Figure 2E] and quantitative FISH [data not shown]) Because overexpressed tankyrase 1 that lacks the NLS ac-
cumulates in the cytoplasm, it does not release TRF1 fromor proliferative capacity (Figure 2F) of GM847 cells, which main-
tain their telomeres by telomerase-independent recombination telomeres (Smith and de Lange, 1999; T.O., H.S., and T.T.,
unpublished data). We established a stable HTC75 cell line that(Dunham et al., 2000).
MST-312 inhibited telomere elongation by FN-tankyrase 1 overexpressed FLAG-tagged tankyrase 1 without NLS (desig-
nated as FLAG-tankyrase 1). As shown in Supplemental Figure(Figure 2G). During the drug treatment, there was no change in
S1, FLAG-tankyrase 1 did not affect TRF1 protein level or telo-expression, self-ADP-ribosylation, or intracellular localization of
mere length. Furthermore, MST-312 effectively shortened telo-FN-tankyrase 1 (data not shown). While the conventional PARP
meres of FLAG-tankyrase 1-overexpressing cells. These find-inhibitor, 3-aminobenzamide (3AB), inhibited poly(ADP-ribosyl)
ings clearly exclude the possibility that MST-312 resistance byation of TRF1 by FN-tankyrase 1 in vitro, MST-312 did not
FN-tankyrase 1 is attributable to enhanced poly(ADP-ribosyl)at-(Figure 2H). Hence, it is unlikely that MST-312 directly inhibits
ing events that are unrelated to telomere length regulation bytankyrase 1 (see also Figure 3). These observations support
TRF1.the idea that telomere elongation by tankyrase 1 depends on
telomerase activity.
However, FN-tankyrase 1 disturbed telomere attrition (Fig- Inhibition of tankyrase 1 by PARP inhibitors
in intact cellsure 2G) and cellular crisis (Figures 4E and 4H, left) by MST-
312. Similarly, FN-tankyrase 1 conferred resistance to telomere Since telomere elongation by FN-tankyrase 1 depends on poly-
(ADP-ribosyl)ation of TRF1 (Cook et al., 2002; Seimiya et al.,shortening through another telomerase inhibitor, EGCG, and
DN-TRF1 also diminished the effect of MST-312 (data not 2004), PARP inhibitory agents may block tankyrase 1 in intact
cells. To explore the possibility, we monitored the “TRF1-releas-shown). Overexpression of FN-tankyrase 1 had no significant
effect on acute cytotoxicity of MST-312 (data not shown). These ing” activity of FN-tankyrase 1 in the presence of PARP inhibi-
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Figure 2. Telomere shortening by MST-312 is disturbed by FN-tankyrase 1
A: HTC75 cells were propagated in the presence of MST-312 at 1 M (day 0–33), 1.25 M (day 33–36), 1.5 M (day 36–40), and 2 M (from day 40). TRFs
at indicated PD were detected by Southern blot analysis.
B: Growth curve of MST-312-treated HTC75 cells.
C: SA--Gal activity in senescent HTC75 cells at PD89. Glutaldehyde-fixed cells were incubated in the acidic X-gal solution at 37C for 3 hr.
D: Apoptosis of MST-312-treated HTC75 cells at PD91. Each value indicates percentage of apoptotic cells quantitated by flow cytometry.
E: Effect of MST-312 on telomere length of GM847 cells. Cells were treated as in A. ALT, alternative lengthening of telomeres.
F: Growth curve of MST-312-treated GM847 cells.
G: Effect of MST-312 on telomere length of FN-tankyrase 1-overexpressing HTC75 cells. Cells were treated as in A from PD20.
H: In vitro PARP assay of FN-tankyrase 1. Whole extracts of mock (pLPC) or FN-tankyrase 1-overexpressing HTC75 cells were immunoprecipitated with anti-
FLAG M2 agarose. The washed beads were incubated with 4 g of GST-TRF1 and 1.3 M [32P]-NAD. 3AB and MST-312 were added prior to addition of
GST-TRF1. Poly(ADP-ribosyl)ated GST-TRF1 was fractionated by SDS-PAGE and detected by autoradiography.
tors. Transient overexpression of FN-tankyrase 1 in HeLa I.2.11 two proteins at the spots (Figure 3Al). Such colocalization is
observed when the PARP activity of FN-tankyrase 1 is abolishedcells results in release of TRF1 from telomeres, which is illus-
trated by disappearance of the immunofluorescent spots of by point mutations (Cook et al., 2002). 3AB did not affect the
expression level or stability of FN-tankyrase 1, which were deter-TRF1 (Figures 3Aa, 3Af, and 3Ak, and Smith and de Lange,
2000). 3AB at 3 mM inhibited the disappearance of these spots mined by Western blot analysis (data not shown). On the other
hand, neither MST-312 nor 3-aminobenzoic acid (3ABA), a 3AB(Figure 3Ab and 3Ag). Since 3AB did not inhibit the interaction
of FN-tankyrase 1 with TRF1, it enhanced colocalization of the analog that does not inhibit PARP activity, affected TRF1 release
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Figure 3. PARP inhibitors block the TRF1 release from telomeres
A: HeLa I.2.11 cells were transiently transfected with FN-tankyrase 1. After 20 hr incubation in the presence of the drugs indicated, cells were fixed with
paraformaldehyde. FN-tankyrase 1 and TRF1 were detected by indirect immunofluorescence stain with anti-FLAG M2 (green; a–e) and anti-TRF1 5747 (red;
f–j) antibodies, respectively. 4,6-diamino-2-phenylindole (DAPI) staining of DNA is shown in blue.
B: Quantitation of the TRF1-releasing activity of FN-tankyrase 1. Column indicates a percentage of the cells in which the telomeric TRF1 spots completely
disappeared. Only the cells that expressed FN-tankyrase 1 were counted. Value in the parentheses indicates the number of counted cells.
(Figures 3Ac, 3Ad, 3Ah, 3Ai, 3Am, and 3An). Consistent with neither of them induced efficient telomere shortening (Figures
4A and 4D, and Table 1) or cell crisis (Figures 4E and 4H, left).these observations, 3AB blocked telomere elongation by
FN-tankyrase 1 in HTC75 cells (Figures 4A and 4D and Table However, a combination of two drugs progressively shortened
telomeres (Figures 4A and 4D, and Table 1) and eventually1). We could not determine the effect of 3ABA on telomere
length, since the cells suffered acute cytotoxicity when treated induced crisis at PD60 (Figures 4E and 4H, left). 3AB at 3–5
mM did not enhance any acute cytotoxicity of MST-312 (datafor more than a week (data not shown). Meanwhile, 3AB did
not inhibit telomere elongation by DN-TRF1 at all (Figure 4B). not shown). 3AB may also inhibit PARP-1, which is involved
in genomic stability (reviewed in Shall and de Murcia, 2000).Together, these observations indicate that the repressive effect
of 3AB on FN-tankyrase 1 is derived from inhibition of its PARP However, while genetic disruption ofPARP-1 causes hypoploidy
and hyperploidy (Kanai et al., 2003), 3 mM 3AB did not affectactivity.
Other PARP inhibitors, such as 4-amino-1,8-naphthalimide the profile of DNA content in HTC75 cells, at least that could
be detected by flow cytometry (data not shown). PJ-34 also(4ANI, 10 M) (Banasik et al., 1992) and PJ-34 (3 M) (Abdel-
karim et al., 2001), also inhibited the TRF1 release at levels cooperated with MST-312 to shorten telomeres and induce cri-
sis of FN-tankyrase 1-transduced cells (Figures 4C, 4F, 4G, andcomparable with 3 mM 3AB (Figures 3Ae, 3Aj, 3Ao, and 3B).
These PARP inhibitors diminished auto-poly(ADP-ribosyl)ation 4H, left, and Table 1). Thus, these PARP inhibitors can reverse
MST-312 resistance that results from FN-tankyrase 1 overex-of FN-tankyrase 1 (data not shown). Furthermore, continuous
treatment of FN-tankyrase 1-overexpressing cells with PJ-34 pression.
While the parental HTC75 cells treated with MST-312 under-significantly reduced telomere elongation (Figures 4C and 4F
went senescence and apoptosis at PD90, when the meanand Table 1). These agents at concentrations used in this study
telomeric restriction fragment (TRF) length was less than 3 kbdid not affect cell growth or telomerase activity (Figures 4E
(Figure 2), FN-tankyrase 1-overexpressing cells treated withand 4G, Supplemental Figure S2, and data not shown). These
MST-312 and 3AB reached crisis with longer TRFs (aroundobservations verify that certain PARP inhibitors block FN-tank-
4 kb). For a more precise view of each chromosome end, weyrase 1 in intact cells. On the other hand, some other PARP
performed telomere peptide nucleic acid (PNA) FISH. As showninhibitors affected telomerase activity (Y.M., H.S. and T.T., un-
in Figures 4I and 4J, combination of MST-312 and PARP inhibi-published observation), and we did not use such inhibitors in
tors increased frequency of the telomere signal-free chromo-this study.
some/chromatid ends. Furthermore, combination of two drugs
induced chromosomal abnormalities (i.e., concomitant treat-PARP inhibitors reverse the MST-312 resistance
in tankyrase 1-overexpressing cells ment with MST-312 and 3AB gave one dicentric chromosome,
3 fusions, and 5 breaks per 10 metaphases at crisis, whereasTo determine if the PARP inhibitors mentioned above restore
the impact of telomerase inhibition, we examined the combined none of these abnormalities were detected in 10 metaphases
of nontreated cells; data not shown). These observations explaineffects of such inhibitors and MST-312. While either MST-312
or 3AB alone inhibited telomere elongation by FN-tankyrase 1, why FN-tankyrase 1-overexpressing cells treated with two drugs
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Figure 4. PARP inhibitors block FN-tankyrase 1 and reverse the MST-312 resistance
A: Effects of 3AB (3 mM) and MST-312 (1–2 M) on telomere elongation by FN-tankyrase 1. FN-tankyrase 1-overexpressing HTC75 cells were treated with
each drug from PD20.
B: Effect of 3AB (3 mM) on telomere elongation by DN-TRF1. Cells were treated with 3AB from PD8.
C: Effects of PJ-34 (3 M) and MST-312 (1–2 M) on telomere elongation by FN-tankyrase 1. Cells were treated with each drug from PD8.
D and F: Graphic representations of telomere length change in FN-tankyrase 1-overexpressing HTC75 cells in the presence of MST-312 and 3AB (D) or PJ-
34 (F).
E and G: Growth curves of the cells in D and F, respectively.
H: FN-tankyrase 1-overexpressing (left) and the parental (right) HTC75 cells were treated with MST-312 as in Figure 2A in the presence or absence of 3 mM
3AB or 3 M PJ-34. Percentages of apoptotic cells were monitored at indicated PD (parentheses).
I: Telomere PNA FISH of FN-tankyrase 1-overexpressing cells. Telomere DNA (red) was visualized on the metaphase chromosomes (blue). Right, magnified
views of typical chromosomes in nontreated cells (upper) and abnormal chromosomes without detectable telomere signals in MST-312 and PJ-34 cotreated
cells (lower).
J: Frequency of the telomere signal-free ends. Percentages of total chromatid ends were shown: one chromosome has four chromatid ends.
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telomerase inhibitor in the latter period of treatment is some-Table 1. Change in telomere length by treatment with MST-312
and PARP inhibitors times much lower than that in the earlier period, although this
issue has not been fully addressed in the original report (AsaiCell
et al., 2003). To reproduce this phenomenon, we used a lower
Compound HTC75/FN-tankyrase 1 HTC75
concentration (0.75 M) of MST-312 to moderately inhibit telo-
Non 35.9  8.2 (6)a 1.2  4.9 (7) merase activity in HTC75 cells. In vitro, 2, 1, and 0.75 M
MST-312 6.6  3.8 (4)b 21.1  2.6 (4) MST-312 inhibited telomerase activity 78%, 69%, and 62%,3AB 6.8  2.6 (3)b 8.1  0.1 (2)
respectively (data not shown). We could not determine the di-PJ-34 6.4 (1)c 3.7  0.1 (2)
MST-312  3AB 46.0  6.2 (3)b 40.4  0.9 (2) minished levels of telomerase activity in intact cells: because
MST-312  PJ-34 26.7 (1)c 40.0 (1) MST-312 is a reversible inhibitor, telomerase activity in the drug-
treated cells revives during preparation of the lysate (SeimiyaCells were continuously treated with each compound for 50–90 PD (treat-
ment with a single compound, which induced later or no crisis) or 30–40 PD et al., 2002). In the presence of 0.75 M MST-312, telomeres
(concomitant treatment with two compounds, which induced earlier crisis). primarily shortened at a rate of 30.0 bp/PD (PD0–PD46, Fig-
Genomic DNA was prepared at several points of population doublings ures 5A and 5B). When the PD exceeded 50, however, MST-(PD), and the mean TRF lengths were determined by Southern blot analysis.
312 could not induce further shortening or cellular crisis, andValues indicate the rates of change in the telomere length (bp) per PD,
which represent slopes of the graphs drawn by PD (x axis) and the mean TRF the average telomere length was stabilized at 3.8 kb. These
length (y axis). Data are presented as means  SD. Repetitions of identical results would not be due to acquired drug resistance, such as
experiments are indicated in parentheses. reduced uptake or enhanced metabolism of MST-312, since
a Monitored within a range between PD8–PD72 because elongation was
acute cytotoxicity of MST-312 did not differ before or after drugsaturated with an increasing number of cell divisions at 	PD80.
treatment at PD88 (data not shown). A chromatin immunopre-b Treatment started at PD20.
c Treatment started at PD8. cipitation assay of telomere DNA (see below) estimated that
average TRF1 loading on each chromosome end in MST-312-
treated cells at PD94 was about 50% of that in untreated cells
(data not shown). These observations suggest that telomere
shortening per se is a resistance factor for telomerase inhibition.reached crisis with longer average telomeres. These findings
3AB did not accelerate the initial rate of telomere shorteningare consistent with the idea that telomere crisis is triggered by
by MST-312 (32 bp/PD, PD0–PD46, Figure 5B). Strikingly,the shortest telomere but not by the average telomere length
however, it maintained the rate of telomere shortening even(Hemann et al., 2001).
beyond the 3.8 kb equilibrium length that was caused by MST-
312 alone (28 bp/PD, from PD46). Furthermore, even after thePARP inhibitors promote the effect of MST-312
effect of MST-312 alone was saturated, combination of 3ABin the parental HTC75 cells
with MST-312 (from PD108) restored additional shortening ofWe next examined the effects of PARP inhibitors on the parental
telomeres (10 bp/PD). By using breast cancer HBC4 cells, weHTC75 cells that did not overexpress exogenous tankyrase 1.
repeated the same experiments and verified that 3AB enhancedHTC75 cells expressed tankyrase 1 at a level that was easily
telomere shortening by MST-312 (Figure 5C). In contrast, 3ABdetectable but was much lower than that seen in FN-tankyrase
had no effect on telomere length in a telomerase-independent1-overexpressing cells (Figure 1A). Continuous treatment of the
GM847 cells (Figure 5D). Similarly, 3AB did not accelerate telo-cells with 3 mM 3AB or 3 M PJ-34 shortened telomeres to a
mere shortening in normal foreskin fibroblasts (Figure 5D). Thus,small extent (Table 1; see also Figure 7C). These effects were
3AB specifically enhanced telomere shortening by MST-312 inmarginal but were observed in multiple experiments. Further-
telomerase-positive cells.more, these PARP inhibitors enhanced telomere shortening by
MST-312 (Table 1) and induced earlier cell crisis onset, which
3AB enhances telomeric association of TRF1was observed at PD35–PD38 (MST-312  3AB) and PD34–
Tankyrase 1 releases TRF1 from telomere DNA in its PARPPD35 (MST-312  PJ-34) (Figure 4H, right). Neither 3AB nor
activity-dependent manner (Cook et al., 2002; Loayza and dePJ-34 increased the percentage of apoptotic cells (Figures 2D
Lange, 2003). To determine if 3AB restores the telomere bindingand 4H, right), indicating that they had little direct effect on
of TRF1, we performed a chromatin immunoprecipitation (ChIP)cellular survival or apoptosis. The average rates of telomere
assay. As shown in Figure 6A, anti-TRF1 antibody precipitatedshortening per PD (Table 1) became similar to those observed
the telomeric TTAGGG but not Alu repetitive elements inin DN-hTERT-transduced HTC75 cells (39.9 bp/PD). On the
HeLaI.2.11 and HTC75 cells. Neither anti-TAB182 (tankyrase 1other hand, 3AB did not enhance telomere shortening by
binding protein of 182 kDa) (Seimiya and Smith, 2002) N termi-DN-hTERT (data not shown), suggesting that DN-hTERT by itself
nus antibody nor preimmune serum precipitated telomere DNA;completely inhibited telomerase activity.
because TAB182 does not colocalize with telomeres, we used
this antibody as a negative control. Consistent with a previousTelomere shortening attenuates the effect
report (Loayza and de Lange, 2003), FN-tankyrase 1-overex-of telomerase inhibition
pressing HTC75 cells reduced the telomere binding of TRF1Since a chromosome end with a shorter telomere has fewer
(Figure 6B). 3AB partially, but statistically significantly, recov-TRF1 molecules (Loayza and de Lange, 2003), telomere shorten-
ered the telomere binding of TRF1, whereas 3ABA had no effect.ing would be functionally equivalent to FN-tankyrase 1 overex-
Although the efficiency of ChIP was much lower than that withpression with respect to TRF1 loading on the chromosome
the anti-TRF1 antibody, anti-tankyrase antibody also precipi-end. Thus, telomere shortening itself may decrease the effect
tated telomere DNA in FN-tankyrase 1-overexpressing cellsof telomerase inhibitors by accelerating access to residual telo-
merase activity. Actually, the rate of telomere shortening by a (Figure 6C). The low values for telomere DNA in ChIP by anti-
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Figure 5. Telomere shortening attenuates the effect of MST-312
A: HTC75 cells were treated with MST-312 (0.75 M) in the presence or absence of 3AB (3 mM). TRFs at indicated PD were detected by Southern blot
analysis.
B: Quantitative representation of A.
C: Breast cancer HBC4 cells were treated as in A. TRFs at indicated PD were detected by Southern blot analysis and the quantitative data are shown.
D: Effect of 3AB (3 mM) on telomere length in GM847 cells and normal foreskin fibroblasts. The quantitative data of Southern blot are shown.
tankyrase antibody are consistent with the previous observation play an auxiliary role for telomere elongation (Seimiya et al.,
2004). We generated the FN-tankyrase 1 deletion mutant, FN-that tankyrase 1 is much less abundant on telomeres than TRF1
(Smith et al., 1998; Loayza and de Lange, 2003; Ye and de tank-ARC V, which retained ARC V but lacked other four ARCs
(Figure 7A). As shown in Figure 7B, overexpression of FN-tank-Lange, 2004). 3AB increased the tankyrase-bound telomere
DNA in the FN-tankyrase 1-overexpressing cells. A similar trend ARC V in HTC75 cells shortened telomeres. The rate of shorten-
ing was moderate (9.3 bp/PD) and very similar to that in HTC75was observed in the parental cells, although it was not statisti-
cally significant, and the efficiency of ChIP was very low. This cells overexpressing TRF1 (van Steensel and de Lange, 1997)
or treated with 3AB or PJ-34 (Table 1 and Figure 7C). In contrast,is consistent with the observation that catalytically inactivated
FN-tankyrase 1 colocalizes with the telomeric TRF1 spots (Fig- neither FN-tank-ARC I, which retained a nonessential ARC I but
lacked ARC II to V, or FN-tank-
ANK, which lost all the fiveure 3A, Cook et al., 2002). Consistent with the observations
that 3AB inhibited telomere elongation by FN-tankyrase 1 but ARCs (Figure 7A), affected telomere length (Figure 7D). Telo-
mere shortening by FN-tank-ARC V was not accelerated by 3ABnot by DN-TRF1 (Figures 4A and 4B), these results indicate
that 3AB settles TRF1 on telomere DNA by inhibiting the PARP (Figure 7B), indicating that FN-tank-ARC V and 3AB shortened
telomeres through the same mechanism.activity of FN-tankyrase 1.
In the parental HTC75 cells or in the MST-312-treated
HTC75 cells (at PD80–PD90 in Figure 5B), ChIP has failed to Discussion
detect a statistically significant effect of 3AB on telomere binding
of TRF1, even under synchronized culture conditions (data not This study has demonstrated that either tankyrase 1 upregula-
tion or telomere shortening lessens the impact of a telomeraseshown). This may be explained by the hypothesis that under
physiological conditions, TRF1 dissociates from telomeres only inhibitor. Concomitant inhibition of tankyrase 1 PARP activity
restored telomere shortening with a telomerase inhibitor. Thesebriefly (e.g.,5 min), if at all, during replication of telomere DNA
(Ohki and Ishikawa, 2004). findings suggest that tankyrase 1, as well as telomerase, may
be a rational target for telomere-directed cancer therapeutics.
One striking difference between telomerase and tankyrase 1 isTelomere shortening by a mutant allele of tankyrase 1
We next examined if moderate telomere shortening by the PARP the expression profile of each protein. While telomerase activity
correlates well with human cancer, tankyrase 1 transcripts wereinhibitors (Table 1) is mimicked by a mutant allele of tankyrase
1. The ankyrin domain of tankyrase 1 has five independent TRF1 almost equally detected in various normal and tumor tissues
(H.S. and T.T., unpublished data). Since tankyrases exist inbinding sites, designated as ANK repeat clusters (ARC) I to V
(Seimiya and Smith, 2002; Seimiya et al., 2004). Among the five various intracellular loci (Smith and de Lange, 1999; Chi and
Lodish, 2000; Lyons et al., 2001), monitoring the nuclear (orARCs, the C-terminal ARC V is essential, whereas ARCs I to IV
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Figure 6. 3AB restores telomere binding of TRF1 in FN-tankyrase 1-overexpressing cells
A: ChIP analysis was performed by using HeLaI.2.11 and HTC75 cell lysates. Cells were fixed with formaldehyde and were sonicated. The resulting lysates
were immunoprecipitated with antibodies or preimmune serum as indicated in triplicate or duplicate. The bead-bound DNA was blotted onto nylon filters.
The filters were hybridized with the probes for TTAGGG (left) or Alu (right) repetitive sequences. For input, 10% of the total DNA samples were applied.
B: FN-tankyrase 1-overexpressing HTC75 cells were treated with 3 mM 3AB or 3ABA for 24 hr or 72 hr. ChIP was performed with anti-TRF1 antibody or
preimmune serum. Quantitative values of the bead-bound telomere DNA (% precipitation relative to the total DNA) are shown in the right. ***p  0.005,
**p  0.01 (unpaired t test).
C: Parental and FN-tankyrase 1-overexpressing HTC75 cells were treated with 3 mM 3AB for 24 hr. ChIP was performed with indicated antibodies. Quantitative
values of the bead-bound telomere DNA are shown in the center panel. To verify the specificity of ChIP, enrichment of telomere DNA relative to Alu
elements (% telomere DNA in ChIP/% Alu elements in ChIP) is also shown (right). *p  0.05 (unpaired t test).
more directly, telomeric) accumulation of tankyrase 1 might telomerase inhibition would not be complete at doses achiev-
able in vivo. We have demonstrated that incomplete inhibitionreveal the different distribution between normal and cancer
cells. Whether or not this is the case, 3AB enhanced telomere of telomerase primarily shortens telomeres to some extent, but
ultimately equilibrates, at which point stabilized telomeres areshortening by MST-312 in telomerase-positive cells but not in
normal or telomerase-independent cells. Thus, although tanky- shorter than those in nontreated cells. If the telomeres at the
equilibrium point were longer than those at crisis (“limit of short-rase 1 expression might not be tumor-specific, we still could
expect that its inhibitory effect on telomere length is specific to ening”), the cells would maintain the protective function of telo-
meres and would not undergo crisis. This situation has beentelomerase-positive target cells.
This work has been originated from the assumption that exemplified by treatment of HTC75 cells with an intentionally
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Figure 7. Tankyrase 1 deletion mutant that short-
ens telomeres
A: Schematic views of FN-tankyrase 1 deletion
mutant constructs. These constructs contain a
FLAG epitope tag and an NLS at the N termini
(not shown). The numbers indicate the positions
of amino acid residues. HPS, region containing
homopolymeric runs of His, Pro, and Ser; ANK,
ankyrin domain; SAM, multimerization domain
homologous to the sterile  motif; PARP, PARP
catalytic domain; ARC, ANK repeat cluster work-
ing as an independent TRF1 binding site; bridge
above two adjacent ANK repeats indicates pres-
ence of a conserved histidine, presumably con-
tributing to inter-repeat stabilization.
B: Effect of overexpression of FN-tank-ARC V on
telomere length in HTC75 cells in the presence
or absence of 3 mM 3AB. The drug treatment
started at PD20. TRFs at indicated PD were de-
tected by Southern blot analysis.
C: Effect of 3 mM 3AB on telomere length in
HTC75 cells.
D: Effects of overexpression of the wild-type
FN-tankyrase 1, FN-tank-ARC I, and FN-tank-

ANK on telomere length in HTC75 cells.
lower dose (0.75 M) of MST-312 (Figures 5A and 5B). On the The rate of telomere shortening in telomerase-negative cells
is proportional to the length of the telomeric 3-overhang (Huff-other hand, if the telomeres at the equilibrium point were shorter
than the limit of shortening, telomere dysfunction would emerge man et al., 2000). Our study indicates that 3AB did not accelerate
telomere shortening in normal fibroblasts at all. Hence, enhance-before the effect of the telomerase inhibitor was saturated. This
has been exemplified by treatment of HTC75 cells with standard ment of telomere shortening by 3AB in MST-312-treated cells
would not be due to extension of the 3-overhang, althoughdoses (1–2 M) of MST-312 (Figures 2A–2D). Since the rates
of telomere shortening in both experiments are slower than other alterations in telomeric structure cannot be excluded.
PARP inhibitors could affect the functions of multiple PARPthose observed in DN-hTERT-infected cells, MST-312 does not
completely inhibit telomerase activity in the cells. Thus, even if family members. Genetic disruption of PARP-1, the most abun-
dant isozyme, causes hypersensitivity to DNA damaging agentscomplete inhibition of telomerase cannot be accomplished, one
can still expect telomere crisis, as exemplified in Figures 2A–2D. (reviewed in Shall and de Murcia, 2000). So far, we have no
evidence that MST-312 triggers a DNA damaging response and,Actually, several groups have reported that telomerase inhibitors
successfully inhibit the growth of human cancer cells that are in fact, 3AB did not enhance acute cytotoxicity of MST-
312. Furthermore, PARP-1 does not poly(ADP-ribosyl)ate TRF1implanted in nude mice (Damm et al., 2001; Asai et al., 2003).
For induction of telomere crisis in HTC75 cells, MST-312 in vitro (Cook et al., 2002). Therefore, combined effects of PARP
inhibitors and MST-312 could not be explained by these mecha-alone required 90 PD, whereas concomitant treatment with
PARP inhibitors required 34–38 PD. Thus, the combined inhibi- nisms, although PARP-1 and PARP-2 still could be involved in
regulation of telomeric functions (d’Adda di Fagagna et al., 1999;tion of tankyrase 1 and telomerase induced telomere dysfunc-
tion 52–56 PD earlier. This means that MST-312 alone allows Dantzer et al., 2004). Since the catalytic efficiency of tankyrase
1 is 150-fold lower as compared to the basal activity of PARP-1a tumor to grow 4.5  1015- to 7.2  1016-fold larger than the
combined inhibition. Since cancer cells often exhibit rather short (Rippmann et al., 2002), PARP inhibitors would differentially
affect the functions of these two enzymes. Furthermore, weaverage telomere length, one can expect that the combined
inhibition produces meaningful clinical results when it is properly have used a lower concentration of 3AB (3 mM) as compared
to previous papers, such as Kanai et al. (2003), in which higherapplied to cancers with short telomeres. Actually, MST-312 can
induce telomere crisis much earlier (i.e., at PD20) in other cells concentration (7 mM) was used to observe the PARP-1-blocked
phenotype. We have shown that FN-tank-ARC V, a mutant allelethat maintain shorter telomere length (Seimiya et al., 2002).
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into pLNCX2 (BD Biosciences). For Myc-DN-TRF1, the partial fragment ofof tankyrase 1, caused moderate telomere shortening (Figure
TRF1(66–385) was amplified by PCR and cloned into pLHCX (BD Biosci-7), presumably by sequestering the functionally crucial ARC
ences) with an N-terminal Myc epitope tag.V of endogenous tankyrase 1 from TRF1 binding. Since this
phenotype was not enhanced by 3AB, telomere shortening by Cell culture and drug treatment
PARP inhibitors would mainly be derived from tankyrase 1 inhibi- HT1080, HTC75 (van Steensel and de Lange, 1997), and HeLaI.2.11 (van
tion. Recently, TIN2 (another TRF1-interacting factor) has been Steensel et al., 1998) cells were grown in DMEM medium supplemented
with 10% heat-inactivated calf serum. Retroviral infection was performedreported as a negative regulator for tankyrase 1-mediated poly
essentially as described (Cook et al., 2002). Infected cells were selected(ADP-ribosyl)ation of TRF1 (Ye and de Lange, 2004). According
with 2 g/ml of puromycin (FN-tankyrase 1), 500 g/ml of G418 (DN-hTERT-to the report, knockdown of TIN2 by small interfering RNA leads
HA), or 200 g/ml of hygromycin (Myc-DN-TRF1). Cells that expressed two
to derepression of endogenous tankyrase 1 at telomeres, re- exogenous constructs were cultured with 25% original concentrations of
sulting in release of TRF1 from telomeres. Importantly, 3AB each drug. Foreskin fibroblasts, GM847, and HBC4 cells were grown in
restores the telomeric localization of TRF1 in TIN2 knockdown DMEM medium with 10% heat-inactivated fetal bovine serum. In cases of
long-term treatment with test compounds, concentrations of puromycin,cells. This indicates that 3AB truly inhibits the activity of endoge-
G418, and hygromycin were further reduced to 25% of the nontreatmentnous tankyrase 1 at telomeres and enhances the telomeric func-
conditions. Cells were split exactly 1:16 (i.e., 4 PD) with test compoundstion of TRF1. Because shorter telomeres are going to have fewer
at concentrations of less than 0.5  IC50, under which conditions cellsTRF1s, telomere shortening may derepress tankyrase 1 action
exhibited almost comparable growth rates with the control; cells needed to
by reducing the TIN2 loading on a chromosome end. This may be split every 3–4 days (5–6 days in case of GM847 and HBC4 cells). Cells
explain why 3AB had a greater impact on shortened telomeres with reduced growth rates at later passages were split 1:2 to 1:8 (i.e., 1
to 3 PD) or given fresh medium with the compounds every 3–4 days.than on longer telomeres, although additional involvement of
other PARPs cannot be excluded.
Western blot analysisIt remains to be determined if tankyrase inhibition causes
Cell lysates were prepared as described (Seimiya et al., 2004). Western blotconsiderable side effects in clinical therapy. Tankyrases are not
analysis was performed as previously described (Seimiya and Smith, 2002)
only found on telomeres, but also in other intracellular loci with with the following primary antibodies: rabbit anti-tankyrase (H-350, 2 g/ml,
additional binding partners, such as insulin-responsive amino- Santa Cruz Biotechnology), rabbit anti-HA (Y-11, 2 g/ml, Santa Cruz Bio-
peptidase, Grb14, and TAB182 (Smith and de Lange, 1999; Chi technology), mouse anti--tubulin (B-5-1-2, 1:1,000, Sigma), rabbit anti-
TRF1 (5747, 0.5 g/ml) (Seimiya et al., 2004), mouse anti-TRF2 (4A794,and Lodish, 2000; Lyons et al., 2001; Seimiya and Smith, 2002).
2.5 g/ml, Imgenex), or mouse anti-lamin A/C (636, 2 g/ml, Santa CruzThese facts suggest yet unidentified physiological functions of
Biotechnology).tankyrases. Interestingly, knockdown of tankyrase 1 by RNA
interference prevents resolution of sister telomere association Detection of telomere DNA
during mitosis (Dynek and Smith, 2004). As compared with its Telomere restriction fragments (TRF) were detected by Southern blot analysis
function on telomere length control, the role of tankyrase 1 for with a [32P]-TTAGGG probe, as previously described (see references in Sei-
miya et al., 2004). The mean length of TRFs was determined on an Attoprogression of mitosis would be less sensitive to PARP inhibi-
densitoscan analyzer, using scanned images of autoradiograms. For telo-tors, because no alteration was observed in mitosis of the PARP
mere PNA FISH, cells were treated with 0.25 g/ml colcemid for 3 hr,inhibitor-treated cells in this study.
trypsinized, and swollen in 0.6% sodium citrate for 30 min at 37C. Meta-TRF1 stalls a replication fork at telomere DNA (Ohki and
phase spreads were prepared on slide glass and dehydrated as described
Ishikawa, 2004), suggesting that TRF1 may need to dissociate (Dynek and Smith, 2004). Telomere PNA FISH was performed essentially as
from telomeres during its replication. Even if this were the case, described (Meeker et al., 2002).
it might be technically difficult, from a physiological standpoint,
Enzyme assaysto detect the release of TRF1 during a very narrow window in
TRAP assay for estimation of telomerase activity was performed as describedthe cell cycle. It would be interesting to determine if any release
(Seimiya et al., 2002). We used a modified set of primers, TS and ACX, andof TRF1 from telomeres is coupled with TIN2-mediated modula-
an internal standard, TSNT, for enhanced accuracy of the quantitation (Kim
tion of tankyrase 1 PARP activity (Ye and de Lange, 2004) in a and Wu, 1997). As pilot studies, we determined the quantitative range of
cell cycle-dependent manner. the reaction by serial dilution of cellular lysates. In vitro PARP assay for
estimation of tankyrase 1 activity was performed as described (Seimiya etFrom a pharmacokinetic aspect, it might be difficult to keep
al., 2004).an enzyme completely static for a long time. We expect that
inhibition of tankyrase 1 will compensate for incomplete inhibi-
Detection of cellular senescence and apoptosis
tion of telomerase. Consequently, this strategy would shorten SA--gal staining was performed as described (Seimiya et al., 2002). For
the time period of drug treatment that is required for the onset quantitation of apoptotic cells, propidium iodide staining of cellular DNA
of telomere crisis and reduce the potential risk of acquired drug and annexin V-fluorescein staining of externalized phosphatidylserine were
performed as previously described (Seimiya and Tsuruo, 1998).resistance. This study also provides a novel application of PARP
inhibitors, and would have an impact on the field of drug devel-
Immunofluorescence microscopyopment for stroke, myocardial ischemia, diabetes, central ner-
HeLaI.2.11 cells were transfected with pLPC/FN-tankyrase 1 using a stan-
vous system injury, and various other forms of PARP-related dard electroporation method. After incubation for 20 hr at 37C, cells were
pathogenesis. fixed with 2% paraformaldehyde/PBS for 10 min and permeabilized with
0.5% NP-40/PBS. Indirect immunofluorescence staining was performed as
Experimental procedures described (Seimiya et al., 2004) with the primary antibodies mouse anti-
FLAG (M2, 2 g/ml) and affinity purified rabbit anti-TRF1 (5747, 1 g/ml)
Plasmids (Seimiya et al., 2004).
pLPC/FN-tankyrase 1 constructs were made as described previously (Sei-
miya et al., 2004). The mutant hTERT(D712A/V713I)-HA (DN-hTERT-HA) Chromatin immunoprecipitation
(Hahn et al., 1999) was created using the HA-tagged hTERT fragment and ChIP was carried out essentially as described by Loayza and de Lange
(2003), except that sonication of lysates was performed at a density of 5 a QuikChange XL site-directed mutagenesis kit (Stratagene) and cloned
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d’Adda di Fagagna, F., Hande, M.P., Tong, W.-M., Lansdorp, P.M., Wang,106 cells/ml. For immunoprecipitation, 50 l of preimmune serum, anti-GST-
Z.-Q., and Jackson, S.P. (1999). Functions of poly(ADP-ribose) polymeraseTRF1 5747, or anti-GST-TAB182 N terminus (a rabbit polyclonal antibody
in controlling telomere length and chromosomal stability. Nat. Genet. 23,418 raised against a recombinant protein for the N-terminal 731 amino acids
76–80.of TAB182; H.S. and S. Smith, unpublished data) antiserum, or 2 g of anti-
tankyrase antibody (H-350) was used per sample. Signals were quantitated d’Adda di Fagagna, F., Reaper, P.M., Clay-Farrace, L., Fiegler, H., Carr, P.,
by phosphorimaging with a Fuji BAS Imaging Analyzer. We confirmed that von Zglinicki, T., Saretzki, G., Carter, N.P., and Jackson, S.P. (2003). A DNA
an excess amount of antibody was added to each ChIP and that the values damage checkpoint response in telomere-initiated senescence. Nature 426,
for telomere DNA in ChIP (%) were maximally saturated. 194–198.
Damm, K., Hemmann, U., Garin-Chesa, P., Hauel, N., Kauffmann, I., Priepke,Supplemental data
H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., et al. (2001). A highlySupplemental data for this article can be found at http://www.cancercell.org/
selective telomerase inhibitor limiting human cancer cell proliferation. EMBO
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